Century Therapeutics, Inc. (IPSC)

NASDAQ: IPSC · IEX Real-Time Price · USD
13.20 0.08 (0.61%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap746.53M
Revenue (ttm)n/a
Net Income (ttm)-83.16M
Shares Out56.56M
EPS (ttm)-4.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume68,941
Open12.98
Previous Close13.12
Day's Range12.80 - 13.57
52-Week Range12.47 - 32.90
Betan/a
AnalystsBuy
Price Target36.00 (+172.7%)
Earnings Daten/a

About IPSC

Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD7...

IndustryBiotechnology
IPO DateJun 18, 2021
Employees102
Stock ExchangeNASDAQ
Ticker SymbolIPSC
Full Company Profile

Analyst Forecast

According to 4 analysts, the average rating for IPSC stock is "Buy." The 12-month stock price forecast is 36.00, which is an increase of 172.73% from the latest price.

Price Target
$36.00
(172.73% upside)
Analyst Consensus: Buy

News

Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies

Century Therapeutics Inc (NASDAQ: IPSC) and Bristol Myers Squibb Co (NYSE: BMY) have announced a research collaboration and license agreement for up to four induced pluripotent stem cell (iPSC) programs...

Other symbols:BMY
1 week ago - Benzinga

Century Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

PHILADELPHIA, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-...

2 weeks ago - GlobeNewsWire

Century Therapeutics Added to the NASDAQ Biotechnology Index

PHILADELPHIA, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-...

1 month ago - GlobeNewsWire

Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology Annual Meeting and Pro...

- In vivo data presented at ASH Annual Meeting demonstrated strong antitumor activity against human lymphoma cell lines with CNTY-101 -

1 month ago - GlobeNewsWire

Century Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

Lead program, CNTY-101 in relapsed/refractory non-Hodgkin's lymphoma, remains on track for IND filing in mid-2022

2 months ago - GlobeNewsWire

Century Therapeutics and Outpace Bio Enter Research Collaboration in CAR Engineering

Collaboration enables Century to explore Outpace's protein solutions for cell therapy to enhance functionality of iPSC platform

3 months ago - GlobeNewsWire

Century Therapeutics Announces Its Addition to the Russell 2000® Index

PHILADELPHIA, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno...

4 months ago - GlobeNewsWire

Century Therapeutics Reports Second Quarter 2021 Financial Results and Business Updates

Continued Company investment across our iPSC platforms, programs, and manufacturing Lead program, CNTY-101, remains on track for IND filing in mid-2022 Recent IPO with net proceeds of approximately $221...

5 months ago - GlobeNewsWire

Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purcha...

PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-...

6 months ago - GlobeNewsWire

Century Therapeutics Announces Pricing of Initial Public Offering

PHILADELPHIA, June 17, 2021 (GLOBE NEWSWIRE) -- Century Therapeutics, an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today...

7 months ago - GlobeNewsWire